Monitoring vaccine safety: a critical component of every immunisation program

Julia M L Brotherton and Michael S Gold
Med J Aust 2008; 189 (5): . || doi: 10.5694/j.1326-5377.2008.tb02012.x
Published online: 1 September 2008

Postmarketing surveillance of vaccine safety requires active input from vaccine providers and health care professionals

Human papillomavirus (HPV) vaccines have now been licensed worldwide and at least 26 million doses have been distributed, including more than 3.7 million in Australia.1 Australia was one of the first countries to implement a universal HPV immunisation program for females aged 12–26 years, commencing in April 2007.

  • Julia M L Brotherton1
  • Michael S Gold2

  • 1 National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, University of Sydney and The Children’s Hospital at Westmead, Sydney, NSW.
  • 2 Discipline of Paediatrics, University of Adelaide, Women’s and Children’s Hospital, Adelaide, SA.



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.